Cargando…

Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer

The approval of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC) has expanded the armamentarium against this disease. This paper will review the historical progress and recent clinical developments of anti-EGFR therapies in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loong, Herbert H., Ma, Brigette B., Chan, Anthony T. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667934/ https://www.ncbi.nlm.nih.gov/pubmed/19365583 http://dx.doi.org/10.1155/2009/967920

Ejemplares similares

Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
por: Azizi, Efat, et al.
Publicado: (2012)

Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck
por: Shaib, Walid, et al.
Publicado: (2012)

Targeted Antiepidermal Growth Factor Receptor (Cetuximab) Immunoliposomes Enhance Cellular Uptake In Vitro and Exhibit Increased Accumulation in an Intracranial Model of Glioblastoma Multiforme
por: Mortensen, Joachim Høg, et al.
Publicado: (2013)

New developments in targeted therapy for metastatic colorectal cancer
por: Wong, Ambrose H. N., et al.
Publicado: (2023)

Update on Anti-EGFR Therapy
por: Chua, Daniel, et al.
Publicado: (2009)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?
por: Marshall, John L.
Publicado: (2009)

Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
por: Chan, Stephen L, et al.
Publicado: (2006)

Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
por: Hutchinson, Ryan A, et al.
Publicado: (2015)

Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)
por: Tougeron, David, et al.
Publicado: (2020)

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
por: Liu, Jiang, et al.
Publicado: (2016)

Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer
por: Valenzuela, Guillermo, et al.
Publicado: (2022)

Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis
por: Wang, Hongchi, et al.
Publicado: (2016)

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma
por: Shen, Chan, et al.
Publicado: (2022)

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
por: Topham, James T., et al.
Publicado: (2023)

Colorectal cancer in Chinese patients: current and emerging treatment options
por: Li, Leung, et al.
Publicado: (2014)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
por: Wang, Lei, et al.
Publicado: (2020)

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer
por: Ouchi, Kota, et al.
Publicado: (2015)

Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes
por: Jang, Jae Yeon, et al.
Publicado: (2023)

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
por: Cassidy, J, et al.
Publicado: (2011)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

Updates in endocrine therapy for metastatic breast cancer
por: Manohar, Poorni M., et al.
Publicado: (2022)

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer
por: Zhang, Ying, et al.
Publicado: (2019)

Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer
por: Ahmed, Mohamed A., et al.
Publicado: (2016)

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
por: Nagaraj, Gayathri, et al.
Publicado: (2020)

Management of metastatic cutaneous melanoma: updates in clinical practice
por: Schvartsman, Gustavo, et al.
Publicado: (2019)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice
por: Schröder, Carsten, et al.
Publicado: (2022)

(111)In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma
por: Shih, Ying-Hsia, et al.
Publicado: (2015)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
por: Larionov, Alexey A.
Publicado: (2018)

Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
por: Jung, Gerhard, et al.
Publicado: (2020)

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
por: Rosati, Gerardo, et al.
Publicado: (2022)

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
por: Florez (DUMA), Narjust, et al.
Publicado: (2023)

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
por: Lee, Shing Fung, et al.
Publicado: (2021)

Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer
por: Ahmed, Mohamed A., et al.
Publicado: (2019)

Overcoming the impact of the COVID‐19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
por: Shimizu, Toshio, et al.
Publicado: (2021)

Colorectal Cancer: Prevention and Management of Metastatic Disease
por: Sugarbaker, Paul H.
Publicado: (2014)

Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
por: Martin, Petra, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dof15ocujikkkv7m78ml1s2p1v